Drug Trial Radar · NCT07229937
A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
189
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.
Conditions
- Hyperlipidemia
Interventions
HRS-1301Drug
HRS-1301 Dose 1,oral
HRS-1301Drug
HRS-1301 Dose 2,oral
HRS-1301Drug
HRS-1301 Dose 3,oral
HRS-1301Drug
HRS-1301 Dose 4,oral
PlaceboDrug
Placebo,oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in LDL-C relative to baselineTime frame: at 12 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The 2nd Affiliated Hospital of Harbin
Harbin, Heilongjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.